公開中のRFP
GHIT Fund RFP Hit-to-Lead Platform 2024-002NEW!
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release July 22, 2024
Intent to Apply No later than 10:00 am Tokyo time on August 30, 2024
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2024-002_Intent to Apply
Full Proposal Due No later than 10:00 am Tokyo time on September 30, 2024
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2024-002_Proposal
Proposals Evaluation and Interview Processes October 2024 - February 2025
Notification of Results February 2025
Investment Agreement Fully Executed (Awarded Proposals) March 2025
製品開発投資のプロセス
